Latest Safety News

NexGen Energy has secured regulatory approval for a significant infrastructure upgrade at its Rook I uranium project, setting the stage for expanded exploration and operational efficiency in 2025.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Capricorn Metals has closed out its last gold hedging contract, becoming fully exposed to gold price fluctuations while securing downside protection through put options. This strategic move positions the company to fund growth projects without additional debt or mandatory hedging.

GenusPlus Group has landed a $130 million contract to upgrade NBN’s Fibre to the Node network across Western Australia, targeting 22,000 properties over the next 3.5 years.

Invion Limited has addressed ASX queries over the timing and content of its cleansing notice, confirming encouraging early results from its Phase I/II non-melanoma skin cancer trial using Photosoft™ technology.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.

QuickFee Limited has launched a Share Purchase Plan offering up to 5 million new shares at a 2% discount, aiming to raise $250,000 to fuel loan book growth and strengthen its balance sheet. Neu Capital Australia Pty Ltd has committed to cover any shortfall, underscoring confidence in QuickFee’s growth trajectory.